Category SLS

SELLAS enters 2026 in a stronger position than it did only a few months ago. The company now has a better-funded balance sheet, a pivotal Phase 3 program that remains the center of gravity for the story, and a second clinical asset that is beginning to matter in a more serious way. That does not make the risk disappear. It simply means the equity story is richer, more credible and more demanding than before.

SELLAS Life Sciences Group (NASDAQ: SLS) is a clinical‑stage biotechnology company focused on cancer immunotherapies and targeted therapies. The current story is driven by the cancer vaccine galinpepimut‑S (GPS), a Wilms Tumor 1 (WT1)–targeting immunotherapy, and by a CDK9 inhibitor program for hematologic and solid tumors.

REGAL Survival Clock, SLS009 Momentum and the Waiting Game
Monthly recap on SELLAS Life Sciences: what changed since the December update, how the 72/80 events in the REGAL Phase 3 trial reshaped the narrative, and which catalysts traders are watching next.

News of the day (REGAL): On 29 December 2025, SELLAS reported that the contract research organization running the Phase 3 REGAL trial notified the company that 72 of the 80 required events (deaths) had occurred as of 26 December 2025. REGAL is an overall survival study; the final analysis will be triggered once 80 events are reached. SELLAS remains fully blinded, and this one-time update does not change the statistical plan. Source: SELLAS REGAL update PR (Dec 29, 2025) .